| |  After treatment with CAR-T cells - immune cells engineered to attack cancer - patients sometimes tell their doctors they feel like they have "brain fog," or forgetfulness and difficulty concentrating. | |
|
| |  A new type of immunotherapy that targets aggressive blood cancers shows promising results alongside manageable side effects, according to the results of an international phase 1/2 clinical trial led by researchers at Washington University School of Medicine in St. Louis. | |
|
| |  Cancer scientists say they have engineered a new type of super-strong antibody which could be used to boost the immune systems of patients fighting the disease. | |
|
| |  Researchers at the National University of Singapore (NUS) have developed a scalable, non-viral technology that efficiently delivers genetic material into human immune cells. | |
|
| |  Scientists have engineered a monoclonal antibody that can protect mice from a lethal dose of influenza A, a new study shows. | |
|
| |  Researchers from the Shenzhen Institutes of Advanced Technology (SIAT), Chinese Academy of Sciences, along with multiple collaborators, have developed a compact diagnostic platform that can evaluate antibody protection against COVID-19 using only a single microliter of fingertip blood. | |
|
| |  Researchers at the Ragon Institute have made a significant discovery about how antibodies can directly enhance the body's ability to fight Mycobacterium tuberculosis (Mtb), the bacteria responsible for tuberculosis (TB). | |
|
| |  The first-in-class antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) demonstrated promising efficacy and high response rates for patients with blastic plasmacytoid dendric cell neoplasm (BPDCN), according to data from a Phase I/II study led by researchers from The University of Texas MD Anderson Cancer Center. | |
|
| |  CAR-T cells are specialized immune cells genetically modified to recognize and attack cancer cells. Researchers at Nagoya University in Japan and their collaborators have developed new CAR-T cells to target malignant tumors. | |
|
| |  A study conducted by researchers at the Center for Cell-Based Therapy (CTC) highlights key proteins and signaling pathways involved in the efficacy of immunotherapy based on CAR-T cells (lymphocytes modified in the laboratory to fight cancer). | |
